Valeant Pharmaceuticals International Inc sought to reassure doctors on Monday that the company’s decision to cut ties to a controversial specialty pharmacy would not disrupt doctors’ ability to prescribe the company’s drugs to patients. In a letter to healthcare professionals seen by Reuters, Chief Executive Michael Pearson said that Valeant would pay for the cost of its products through Nov. 8 and make sure patients could fill their prescriptions with no out-of-pocket expenses, wherever possible.